Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.35 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52571 | 0.88 | CYP2C9 (0.44) | CYP2C9KCNH2SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL51744 | 0.88 | CYP2C9 (0.44) | CYP2C9KCNH2SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL52508 | 0.87 | CYP2C9 (0.49) | CYP2C9KCNH2SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL52664 | 0.86 | CYP2C9 (0.55) | CYP2C9KCNH2SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL51736 | 0.85 | CYP2C9 (0.48) | CYP2C9KCNH2SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL52289 | 0.85 | CYP2C9 (0.48) | CYP2C9KCNH2SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL52357 | 0.85 | CYP2C9 (0.48) | CYP2C9KCNH2SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL51836 | 0.85 | CYP2C9 (0.48) | CYP2C9KCNH2SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL52451 | 0.85 | CYP2C9 (0.48) | CYP2C9KCNH2SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL52619 | 0.84 | CYP2C9 (0.47) | CYP2C9KCNH2SMN1; SMN2KCNE1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | CYP2C9 602/4885KCNH2 3969/4885SMN1; SMN2 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.